Published in Nat Rev Immunol on December 02, 2011
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell (2016) 2.09
MYC regulates the antitumor immune response through CD47 and PD-L1. Science (2016) 1.87
CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis. BMC Syst Biol (2015) 1.12
New cast for a new era: preclinical cancer drug development revisited. J Clin Invest (2013) 1.11
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat Med (2013) 1.07
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology (2014) 0.95
Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med (2014) 0.92
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol (2013) 0.89
Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. Nat Med (2013) 0.83
T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN-γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. Cell Rep (2015) 0.82
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol (2016) 0.80
Combination immunotherapy: a road map. J Immunother Cancer (2017) 0.77
The Promise of Preventive Cancer Vaccines. Vaccines (Basel) (2015) 0.77
Neutrophils: Critical components in experimental animal models of cancer. Semin Immunol (2016) 0.77
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. Oncology (Williston Park) (2015) 0.77
Microfluidics: A new tool for modeling cancer-immune interactions. Trends Cancer (2016) 0.76
Intensifying tumour immunity through combination therapy. Lancet Oncol (2012) 0.76
Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. Eur J Nucl Med Mol Imaging (2016) 0.75
Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. Hum Vaccin Immunother (2014) 0.75
Regulatory considerations for clinical development of cancer vaccines. Hum Vaccin Immunother (2014) 0.75
Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. Oncotarget (2016) 0.75
Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. Front Pharmacol (2017) 0.75
Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. Cancer J (2016) 0.75
Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response. J Vis Exp (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Cancer-related inflammation. Nature (2008) 34.21
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Immunity, inflammation, and cancer. Cell (2010) 28.27
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res (1960) 5.31
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature (1959) 3.67
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res (2009) 2.97
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res (1970) 1.73
The makings of a tumor rejection antigen. Immunity (1999) 1.71
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 1.71
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine (2007) 1.58
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res (2001) 1.47
Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol (2004) 1.46
Dual roles for immunity in gastrointestinal cancers. J Clin Oncol (2010) 1.31
A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest (2011) 1.25
A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res (2010) 1.21
Vaccination for treatment and prevention of cancer in animal models. Adv Immunol (2006) 1.11
Bioluminescent imaging of melanoma in live mice. J Invest Dermatol (2005) 1.08
Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A (1982) 1.07
Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin Cancer Res (2009) 0.99